Trial Profile
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel; Temozolomide
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms BROCADE
- Sponsors Abbott Laboratories; AbbVie; AbbVie Germany
- 22 Oct 2020 Status changed from active, no longer recruiting to completed.
- 18 Mar 2020 Planned End Date changed from 23 Jan 2020 to 24 Dec 2020.
- 12 Nov 2019 Planned End Date changed from 28 Sep 2019 to 23 Jan 2020.